Fairvalue-Calculator Fairvalue-Calculator
EN DE

A Plus Biotechnology Co (6918) Fair Value & Analysis

Healthcare · TW · Market cap 2.5B TWD

Price73.50 TWD
Fair Value99.43 TWD
Upside+35.3%
Quality95/100
Evidence: High Range 74.47 TWD – 124.29 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

A Plus Biotechnology Co (6918) currently trades at 73.50 TWD, while our model-based Fair Value estimate is 99.43 TWD — implying the stock looks roughly 35.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of orthopedic and other medical devices. The company offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, biologics. It also provides bone grafts. A Plus Biotechnology Co., Ltd. was founded in 2009 and is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -95% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is A Plus Biotechnology Co (6918) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 99.43 TWD versus a price of 73.50 TWD — about +35% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6918?
Our 21-model fair value for A Plus Biotechnology Co is 99.43 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 73.50 TWD.
What is the quality score of 6918?
A Plus Biotechnology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.